The Indian drug regulator’s subject expert committee (SEC) has approved Bharat Biotech’s locally-made Covid-19 vaccine, Covaxin, for emergency use in the country, the union health ministry said on Saturday evening.
This is the second vaccine to be cleared for India after the Oxford-AstraZeneca vaccine got the go-ahead on Friday evening.
Confirming the accelerated approval, the health ministry said that the SEC has granted permission to Covaxin for restricted emergency use "in public interest as an abundant precaution, in clinical trial mode, especially in the context of infection by mutant strains".
The committee constituted by Central Drug Standard Control Organisation had on Friday maintained that the data provided by Bharat Biotech for its coronavirus vaccine was not sufficient for grant of emergency use approval and had asked for more information, but granted its approval on Saturday..
India decisively asserted its military superiority over Pakistan during this month's brief but intense conflict,…
Trade associations and local business groups in Pakistan-occupied Gilgit-Baltistan (PoGB) launched an indefinite protest on…
A human chain and protest march was organized by various organizations in front of the…
The United States on Saturday announced the expansion of its security partnerships with India through…
Highlighting the use of indigenous platforms during Operation Sindoor, Chief of Defence Staff (CDS) General…
Congress MP Shashi Tharoor on Friday (local time) said that Colombia will issue a statement…
